Home > Healthcare > Medical Devices > Therapeutic Devices > artificial pancreas device systems market
Get a free sample of Artificial Pancreas Device Systems (APDS) Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Artificial Pancreas Device Systems (APDS) Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The ADPS industry is consolidated in nature with major companies competing to offer superior APDS in this business space. Medtronic Plc, Johnson & Johnson Services Inc, Bigfoot Biomedical, Tandem Diabetes Care, Inc., Pancreum, Inc, etc. are some of the major players holding majority of share in this market. These companies are focusing their efforts on continuous product innovation in order to acquire substantial market share. For instance, Medtronic Plc is engaged in developing advanced artificial pancreas system. Other companies such as Johnson & Johnson Services Inc, Bigfoot Biomedical are focusing on bringing advanced products to the market to gain competitive advantage and expand their client base. The major strategies adopted by the company involves geographical expansion, new product launch, distribution agreements, etc.
Some of the eminent market participants operating in in the artificial pancreas device systems industry include:
U.S. artificial pancreas device systems industry accounted for USD 122 million in 2022 and is predicted to witness substantial growth through 2032 due to the surge in the diabetes population base in the country.
Medtronic Plc, Johnson & Johnson Services Inc., Bigfoot Biomedical, Tandem Diabetes Care, Inc., Pancreum, Inc., TypeZero Technologies, LLC, Beta Bionics, Insulet Corporation, Defymed, Inreda Diabetic, and Diabeloop.
The threshold suspends device systems segment garnered USD 175 million in 2022 and will grow through 2032 attributed to the advanced safety features of these devices.
The global artificial pancreas device systems industry was valued at USD 331 million in 2022 and is estimated to account for USD 757.5 million by 2032.